• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化和肝癌中抗凝血酶III的代谢

Metabolism of antithrombin III in cirrhosis and carcinoma of the liver.

作者信息

Chan V, Lai C L, Chan T K

出版信息

Clin Sci (Lond). 1981 Jun;60(6):681-8. doi: 10.1042/cs0600681.

DOI:10.1042/cs0600681
PMID:6265140
Abstract
  1. The metabolism of human antithrombin III (ATIII) was studied by using 125I-labelled tracer. 2. The plasma half-life (t0.5) was 2.71 +/- 0.26 days in normal subjects and was similar in patients with cirrhosis or primary carcinoma of liver. 3. Patients with cirrhosis had low ATIII levels, decreased intravascular mass, total body mass and decreased absolute catabolic rate, suggesting decreased synthesis. The positive correlation of ATIII level with fractional catabolic rate (K10) indicated that the decreased catabolic might exert a positive inhibition on ATIII production. 4. These abnormalities were more exaggerated in patients with macronodular cirrhosis associated with hepatitis surface antigen or in those with ascites. 5. In cirrhotic patients with ascites an additional extravascular pool of ATIII was present which did not turn over at the same rate as the intravascular pool. 6. Patients with primary carcinoma of liver had moderately low ATIII, but normal intravascular mass and total body mass because of the increased plasma volume and normal absolute catabolic rate. 7. The negative correlation of ATIII levels with K10 suggested that the low levels could be due to increased catabolism or consumption. 8. One patient with disseminated malignancy and active superficial thrombophlebitis had normal ATIII metabolism.
摘要
  1. 采用¹²⁵I标记示踪剂研究了人抗凝血酶III(ATIII)的代谢。2. 正常受试者血浆半衰期(t0.5)为2.71±0.26天,肝硬化或原发性肝癌患者的血浆半衰期与之相似。3. 肝硬化患者ATIII水平降低,血管内质量、全身质量下降,绝对分解代谢率降低,提示合成减少。ATIII水平与分数分解代谢率(K10)呈正相关,表明分解代谢降低可能对ATIII产生起到正性抑制作用。4. 这些异常在伴有乙肝表面抗原的大结节性肝硬化患者或有腹水的患者中更为明显。5. 有腹水的肝硬化患者存在一个额外的血管外ATIII池,其周转速度与血管内池不同。6. 原发性肝癌患者的ATIII水平中度降低,但由于血浆量增加和绝对分解代谢率正常,其血管内质量和全身质量正常。7. ATIII水平与K10呈负相关,提示低水平可能是由于分解代谢增加或消耗所致。8. 一名患有播散性恶性肿瘤和活动性浅表血栓性静脉炎的患者ATIII代谢正常。

相似文献

1
Metabolism of antithrombin III in cirrhosis and carcinoma of the liver.肝硬化和肝癌中抗凝血酶III的代谢
Clin Sci (Lond). 1981 Jun;60(6):681-8. doi: 10.1042/cs0600681.
2
Metabolism of fibrinogen in cirrhosis of the liver.肝脏肝硬化中纤维蛋白原的代谢
J Clin Invest. 1971 Aug;50(8):1690-701. doi: 10.1172/JCI106658.
3
Antithrombin III transfusion in patients with hepatic cirrhosis.肝硬化患者的抗凝血酶III输注
Br J Haematol. 1982 Sep;52(1):25-33. doi: 10.1111/j.1365-2141.1982.tb03858.x.
4
Antithrombin III metabolism in patients with liver disease.肝病患者的抗凝血酶III代谢
J Clin Pathol. 1984 May;37(5):523-30. doi: 10.1136/jcp.37.5.523.
5
Catabolism and distribution of functionally heterogeneous human antithrombin III.
J Lab Clin Med. 1987 Jan;109(1):89-96.
6
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.人体内抗凝血酶III(肝素辅因子)的代谢:静脉血栓形成及肝素给药的影响。
Eur J Clin Invest. 1977 Feb;7(1):27-35. doi: 10.1111/j.1365-2362.1977.tb01566.x.
7
Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.抗凝血酶III浓缩剂治疗先天性和获得性抗凝血酶缺乏症的临床经验。抗凝血酶III研究组。
Am J Med. 1989 Sep 11;87(3B):53S-60S. doi: 10.1016/0002-9343(89)80533-9.
8
Some immunological investigations on antithrombin III 'Budapest'.关于抗凝血酶III“布达佩斯”的一些免疫学研究。
Br J Haematol. 1978 Nov;40(3):459-70. doi: 10.1111/j.1365-2141.1978.tb05817.x.
9
Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span.家族性抗凝血酶III(ATIII)缺乏症患者的输血研究:输注ATIII的半衰期及这种输注对血小板寿命的影响。
Br J Haematol. 1981 Nov;49(3):449-53. doi: 10.1111/j.1365-2141.1981.tb07248.x.
10
Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy.肝癌患者根治性肝切除术后抗凝血酶 III 水平对预后的意义。
Ann Surg Oncol. 2012 Sep;19(9):2888-96. doi: 10.1245/s10434-012-2338-y. Epub 2012 Mar 31.

引用本文的文献

1
Antithrombin III metabolism in patients with liver disease.肝病患者的抗凝血酶III代谢
J Clin Pathol. 1984 May;37(5):523-30. doi: 10.1136/jcp.37.5.523.
2
In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment.放射性碘化兔抗凝血酶III的体内行为。非循环血管腔室的证明。
J Clin Invest. 1984 Jul;74(1):191-9. doi: 10.1172/JCI111401.
3
Proteases and antiproteases related to the coagulation system in plasma and ascites--an approach to differentiate between malignant and cirrhotic ascites.
血浆和腹水中与凝血系统相关的蛋白酶和抗蛋白酶——一种区分恶性腹水和肝硬化腹水的方法
Klin Wochenschr. 1987 Jul 15;65(14):634-8. doi: 10.1007/BF01875497.